Novo Nordisk AS's sales in the second quarter were DKK 76.86 billion, while the market estimate was DKK 76.99 billion
I'm PortAI, I can summarize articles.
In the second quarter, Novo Nordisk's sales of Wegovy reached DKK 19.53 billion, exceeding market expectations of DKK 19 billion. Risk warning and disclaimer: The market carries risks, and investments should be made with caution. This article does not constitute personal investment advice and does not take into account the specific investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investment based on this is at one's own risk
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments